Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J L Teillaud

Showing results (1-10 of 95) with videos related to

Pageof 10
Sort By:
Pathologie-Biologie|November 26, 1999
[A therapeutic Trojan horse: intracellular antibodies]J L Teillaud
Research in Immunology|March 1, 1989
Are Ts cells involved in isotype-specific regulation?J L Teillaud, W H Fridman
Trends in Biotechnology|May 1, 1997
Phage display and antibody engineering: a French overviewL Aujame, R Sodoyer, J L Teillaud
Hybridoma|April 1, 1992
Monoclonal antibodies against bacterial glucosamine 6-phosphate synthase: production and use for structural studiesO Cochet, B Badet, J L Teillaud
Gene Therapy|March 15, 2002
Bypassing tumor-specific and bispecific antibodies: triggering of antitumor immunity by expression of anti-FcgammaR scFv on cancer cell surfaceN Gruel, W H Fridman, J L Teillaud
Immunology Letters|March 1, 1989
Immunoglobulin-binding factorsW H Fridman, C Sautès, J L Teillaud
Annual Review of Microbiology|January 1, 1984
Monoclonal antibodies: a powerful tool for selecting and analyzing mutations in antigens and antibodiesR R Pollock, J L Teillaud, M D Scharff
Immunology Letters|July 29, 1999
Vav and SLP-76 recruitment by cross-linking of FcgammaRIIa1 in promyelocytic HL-60 cellsH Rouard, S Tamasdan, W H Fridman, et al.
Cancer Detection and Prevention|November 26, 1999
Ras and p53 intracellular targeting with recombinant single-chain Fv (scFv) fragments: a novel approach for cancer therapy?O Cochet, N Gruel, W H Fridman, et al.
Preparative Biochemistry & Biotechnology|January 5, 2002
Purification of soluble recombinant human FcgammaRII (CD32)N Gruel, J Chapiro, W H Fridman, et al.
Pageof 10

Showing results (1-10 of 95) with videos related to

Sort By:
Pageof 10
Pathologie-Biologie|November 26, 1999
[A therapeutic Trojan horse: intracellular antibodies]J L Teillaud
Research in Immunology|March 1, 1989
Are Ts cells involved in isotype-specific regulation?J L Teillaud, W H Fridman
Trends in Biotechnology|May 1, 1997
Phage display and antibody engineering: a French overviewL Aujame, R Sodoyer, J L Teillaud
Hybridoma|April 1, 1992
Monoclonal antibodies against bacterial glucosamine 6-phosphate synthase: production and use for structural studiesO Cochet, B Badet, J L Teillaud
Gene Therapy|March 15, 2002
Bypassing tumor-specific and bispecific antibodies: triggering of antitumor immunity by expression of anti-FcgammaR scFv on cancer cell surfaceN Gruel, W H Fridman, J L Teillaud
Immunology Letters|March 1, 1989
Immunoglobulin-binding factorsW H Fridman, C Sautès, J L Teillaud
Annual Review of Microbiology|January 1, 1984
Monoclonal antibodies: a powerful tool for selecting and analyzing mutations in antigens and antibodiesR R Pollock, J L Teillaud, M D Scharff
Immunology Letters|July 29, 1999
Vav and SLP-76 recruitment by cross-linking of FcgammaRIIa1 in promyelocytic HL-60 cellsH Rouard, S Tamasdan, W H Fridman, et al.
Cancer Detection and Prevention|November 26, 1999
Ras and p53 intracellular targeting with recombinant single-chain Fv (scFv) fragments: a novel approach for cancer therapy?O Cochet, N Gruel, W H Fridman, et al.
Preparative Biochemistry & Biotechnology|January 5, 2002
Purification of soluble recombinant human FcgammaRII (CD32)N Gruel, J Chapiro, W H Fridman, et al.
Pageof 10